1ROVI Stock Overview

Manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. More details

1ROVI fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	3/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 50.3% below our estimate of its fair value

Earnings are forecast to grow 16.65% per year

Analysts in good agreement that stock price will rise by 52.8%

Risk Analysis

No risks detected for 1ROVI from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Laboratorios Farmaceuticos Rovi, S.A. Competitors

Recordati Industria Chimica e Farmaceutica

BIT:REC

€11.0b

Tasly Pharmaceutical Group

SHSE:600535

CN¥22.7b

Aspen Pharmacare Holdings

JSE:APN

R53.0b

Tianjin Pharmaceutical Da Ren Tang Group

SHSE:600329

CN¥20.0b

Price History & Performance

Summary of share price highs, lows and changes for Laboratorios Farmaceuticos Rovi
Historical stock prices
Current Share Price	€52.30
52 Week High	€0
52 Week Low	€0
Beta	0.42
1 Month Change	3.56%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-3.15%

Recent updates

Shareholder Returns

	1ROVI	IT Pharmaceuticals	IT Market
7D	1.7%	4.2%	3.0%
1Y	n/a	-12.4%	12.6%

Return vs Industry: Insufficient data to determine how 1ROVI performed against the Italian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 1ROVI performed against the Italian Market.

Price Volatility

Is 1ROVI's price volatile compared to industry and market?
1ROVI volatility
1ROVI Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	5.3%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1ROVI has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1ROVI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1946	2,197	Juan Lopez-Belmonte Encina	www.rovi.es

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi.

Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary

How do Laboratorios Farmaceuticos Rovi's earnings and revenue compare to its market cap?
1ROVI fundamental statistics
Market cap	€2.68b
Earnings (TTM)	€136.88m
Revenue (TTM)	€763.75m

19.6x

P/E Ratio

3.5x

P/S Ratio

Is 1ROVI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1ROVI income statement (TTM)
Revenue	€763.75m
Cost of Revenue	€296.04m
Gross Profit	€467.71m
Other Expenses	€330.83m
Earnings	€136.88m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	2.68
Gross Margin	61.24%
Net Profit Margin	17.92%
Debt/Equity Ratio	16.9%

How did 1ROVI perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

35%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/05 12:08
End of Day Share Price	2025/05/05 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Laboratorios Farmaceuticos Rovi, S.A. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Álvaro Arístegui Echevarría	Ahorro Corporación
Guilherme Sampaio	Banco BPI, S.A.
Luis Arredondo	Banco de Sabadell. S.A.

Laboratorios Farmaceuticos Rovi BIT:1ROVI Stock Report